Liposomal Annamycin Reconstitution with Temperature and pH Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Annamycin, a cancer chemotherapeutic agent with anthracene structure, presents formulation challenges due to its physical and inherent instability, leading to decomposition and impurities, which affect dosage efficacy and regulatory compliance.
Innovation Solution
A method of reconstituting preliposomal Annamycin lyophilizate by adding pre-warmed saline at 30-45°C to form a liposomal suspension, maintaining at 30-45°C, and diluting with pre-warmed saline to achieve concentrations of 0.5-1.5 mg/mL, followed by careful handling and storage at 37°C ± 4°C to ensure stability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If preliposomal Annamycin lyophilizate is reconstituted using conventional methods, then the drug can be prepared for administration, but the formulation decomposes and generates impurities due to instability under certain conditions
Solution Approach 1:
The patent applies parameter changes by controlling temperature (maintaining 37°C throughout reconstitution and storage) and pH (using citrate buffer at pH 3.0-5.0) to prevent decomposition of Annamycin. This temperature and pH control resolves the contradiction by creating stable conditions that prevent harmful decomposition while maintaining drug efficacy.
Solution Approach 2:
The patent uses citrate buffer as an intermediary substance to stabilize the Annamycin formulation during reconstitution. The buffer mediates between the lyophilized powder and saline, maintaining optimal pH conditions that prevent decomposition and impurity formation while enabling proper drug reconstitution.
2Reliability
If Annamycin is formulated as a liposome to improve delivery, then drug delivery efficacy is enhanced, but the formulation becomes inherently unstable under certain conditions
Solution Approach 1:
The patent maintains the liposomal formulation at 37°C throughout reconstitution and storage, which optimizes the physical state of the lipids and prevents aggregation or degradation. This temperature control resolves the contradiction by maintaining liposomal integrity while preserving drug delivery capabilities.
Solution Approach 2:
The patent uses an inert atmosphere (nitrogen or carbon dioxide) during lyophilization and storage to protect the liposomal Annamycin from oxidation and other environmental degradation. This creates a stable environment that preserves formulation integrity while maintaining drug delivery efficacy.
3Ease of manufacture
If the drug is reconstituted without temperature control, then the process is simpler, but the drug decomposes and becomes ineffective
Solution Approach 1:
The patent pre-warms all components (saline, syringes, IV bags, and the reconstitution environment) to 37°C before beginning the reconstitution process. This preliminary temperature equilibration simplifies the process by eliminating the need for complex temperature control during mixing, while ensuring drug stability and effectiveness is maintained throughout.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a stable and pure liposomal Annamycin formulation with improved uniformity, ensuring consistent dosage and compliance with regulatory standards, reducing waste and side effects.
Implementation Method 1
adding pre-warmed saline having a temperature of 30-45 °C to one or more containers of preliposomal Annamycin lyophilizate, to form suspended liposomal Annamycin
Implementation Method 2
maintaining said one or more containers at 30 -45 °C; diluting said suspended liposomal Annamycin, with pre-warmed saline having a temperature of 30-45 °C
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.